Clinical studies to date with CAR-T treatments for cancer therapy have demonstrated strong potential for CAR-T to become another standard of treatment in specific cancer diseases. However, in all of those studies, a common side effect named Cytokine Release Syndrome, also referred to as CRS, has affected a high percentage of the study participants. The severe form of CRS, named sCRS, can lead to significant patient risk via multiple organ failure. This side effect may have the potential of limiting the applicability of the CAR-T treatments for non-hospitalized cancer patients. In Juno Therapeutics’ JCAR015 study, 39% of the 23 adult patients experienced sCRS, and in its JCAR014 study 29% of the 52 adult patients experienced sCRS. In the Novartis CTL019 study, 27% of the patient experienced sCRS. We believe that Allocetra could be utilized, in combination with CAR-T therapies, to prevent or dramatically reduce the occurrences of sCRS in CAR-T treatments, without affecting the efficacy of the cancer treatments, similarly to Allocetra’s currently demonstrated effect on GvHD post bone marrow transplantations. Unlike “safety switch” CAR-T solutions that are in development by several companies, including Bellicum Pharmaceuticals, Inc., in which there is a way to “kill” the CAR-T cells swiftly as treatment to the sCRS, the Allocetra solution is not designed to terminate the CAR-T cells. As such, Allocetra would potentially allow for prevention of sCRS without affecting the efficacy of the CAR-T cells in curing the cancer disease. We are conducting various preclinical studies to analyze the Allocetra dosing and effect in combination with CAR-T treatments.